Hengrui Pharmaceutical's innovative drug, the nec acid famini capsule, was approved clinically.

Guide: The nec acid famini capsule is a small molecule multi-target tyrosine kinase inhibitor.
. Recently, Hengrui Pharmaceuticals received a "Drug Clinical Trial Approval Notice" approved by the State Drug Administration, approving the company to carry out a randomized, open, controlled, multi-center Phase III clinical study of the innovative drug nephloric acid firminiry to treat advanced gastrointestinal mesothelioma, which failed to be treated by imatini.
gastrointestinal mesothelioma (gastrointestinal stromaltumor, GIST) is a type of soft tissue sarcoma, the incidence rate of about one-fifth of all soft tissue sarcoma, is the most common type of soft tissue sarcoma, accounting for 1% to 3% of all gastrointestinal malignancies.
GIST can occur anywhere in the gastrointestinal tract, including the retina, intestinal membrane and peritina, but mainly in the stomach and small intestine. the clinical manifestations of
GIST are determined by the site and size of the tumor, the most common symptoms are anemia, weight loss, gastrointestinal bleeding, abdominal pain and lump-related symptoms, but also acute abdominal disease, obstruction, intestinal stacking, perforation or rupture and periaryitis.
For systemic treatment of advanced gastrointestinal mesothelioma, in addition to the limited type of gene mutation, the first line usually chooses imatinib treatment, imatinib treatment failed only one option, and after the failure of Imatrini and Schoinib treatment, although a variety of drugs have been proven to be effective, but its efficacy is not ideal.
the apple acid formidni capsule is a small molecule multi-target tyrosine kinase inhibitor developed by Hengrui Pharmaceutical Innovation, which has good inhibitory activity on a variety of subjects tyrosine kinase.
in a phase II study conducted by Hengrui Pharmaceuticals on the treatment of imatiniid in the failed treatment of advanced gastrointestinal mesothelioma (GIST), famini showed significant initial efficacy.
Combining the results of preclinical and preclinical studies, it is proposed to conduct a Phase III study of the treatment of advanced gastrointestinal mesothelioma (GIST) in which the treatment of Imatrione failed, to confirm the effectiveness of the treatment of failed advanced gastrointestinal mesothelioma in the treatment of ematrini, and to provide more treatment options for patients with late-stage GIST who failed treatment of imatini.
.